Human Neural Stem Cell Extracellular Vesicles Improve Tissue and Functional Recovery in the Murine Thromboembolic Stroke Model

Robin L. Webb, Erin E. Kaiser, Shelley L. Scoville, Tyler A. Thompson, Sumbul Fatima, Chirayukumar D Pandya, Karishma Sriram, Raymond L. Swetenburg, Kumar Vaibhav, Ali Syed Arbab, Babak Baban, Krishnan Michael Dhandapani, David C Hess, MD Nasrul Hoda, Steven L. Stice

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Over 700 drugs have failed in stroke clinical trials, an unprecedented rate thought to be attributed in part to limited and isolated testing often solely in “young” rodent models and focusing on a single secondary injury mechanism. Here, extracellular vesicles (EVs), nanometer-sized cell signaling particles, were tested in a mouse thromboembolic (TE) stroke model. Neural stem cell (NSC) and mesenchymal stem cell (MSC) EVs derived from the same pluripotent stem cell (PSC) line were evaluated for changes in infarct volume as well as sensorimotor function. NSC EVs improved cellular, tissue, and functional outcomes in middle-aged rodents, whereas MSC EVs were less effective. Acute differences in lesion volume following NSC EV treatment were corroborated by MRI in 18-month-old aged rodents. NSC EV treatment has a positive effect on motor function in the aged rodent as indicated by beam walk, instances of foot faults, and strength evaluated by hanging wire test. Increased time with a novel object also indicated that NSC EVs improved episodic memory formation in the rodent. The therapeutic effect of NSC EVs appears to be mediated by altering the systemic immune response. These data strongly support further preclinical development of a NSC EV-based stroke therapy and warrant their testing in combination with FDA-approved stroke therapies.

Original languageEnglish (US)
Pages (from-to)530-539
Number of pages10
JournalTranslational Stroke Research
Volume9
Issue number5
DOIs
StatePublished - Oct 1 2018

Fingerprint

Neural Stem Cells
Stroke
Rodentia
Mesenchymal Stromal Cells
Extracellular Vesicles
Pluripotent Stem Cells
Episodic Memory
Therapeutic Uses
Foot
Clinical Trials
Cell Line
Wounds and Injuries

Keywords

  • Neural stem cell extracellular vesicles
  • Preclinical stroke model
  • Thromboembolic stroke

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Webb, R. L., Kaiser, E. E., Scoville, S. L., Thompson, T. A., Fatima, S., Pandya, C. D., ... Stice, S. L. (2018). Human Neural Stem Cell Extracellular Vesicles Improve Tissue and Functional Recovery in the Murine Thromboembolic Stroke Model. Translational Stroke Research, 9(5), 530-539. https://doi.org/10.1007/s12975-017-0599-2

Human Neural Stem Cell Extracellular Vesicles Improve Tissue and Functional Recovery in the Murine Thromboembolic Stroke Model. / Webb, Robin L.; Kaiser, Erin E.; Scoville, Shelley L.; Thompson, Tyler A.; Fatima, Sumbul; Pandya, Chirayukumar D; Sriram, Karishma; Swetenburg, Raymond L.; Vaibhav, Kumar; Arbab, Ali Syed; Baban, Babak; Dhandapani, Krishnan Michael; Hess, David C; Hoda, MD Nasrul; Stice, Steven L.

In: Translational Stroke Research, Vol. 9, No. 5, 01.10.2018, p. 530-539.

Research output: Contribution to journalArticle

Webb, Robin L. ; Kaiser, Erin E. ; Scoville, Shelley L. ; Thompson, Tyler A. ; Fatima, Sumbul ; Pandya, Chirayukumar D ; Sriram, Karishma ; Swetenburg, Raymond L. ; Vaibhav, Kumar ; Arbab, Ali Syed ; Baban, Babak ; Dhandapani, Krishnan Michael ; Hess, David C ; Hoda, MD Nasrul ; Stice, Steven L. / Human Neural Stem Cell Extracellular Vesicles Improve Tissue and Functional Recovery in the Murine Thromboembolic Stroke Model. In: Translational Stroke Research. 2018 ; Vol. 9, No. 5. pp. 530-539.
@article{a86d35fc238f4a5299906c27bb245a06,
title = "Human Neural Stem Cell Extracellular Vesicles Improve Tissue and Functional Recovery in the Murine Thromboembolic Stroke Model",
abstract = "Over 700 drugs have failed in stroke clinical trials, an unprecedented rate thought to be attributed in part to limited and isolated testing often solely in “young” rodent models and focusing on a single secondary injury mechanism. Here, extracellular vesicles (EVs), nanometer-sized cell signaling particles, were tested in a mouse thromboembolic (TE) stroke model. Neural stem cell (NSC) and mesenchymal stem cell (MSC) EVs derived from the same pluripotent stem cell (PSC) line were evaluated for changes in infarct volume as well as sensorimotor function. NSC EVs improved cellular, tissue, and functional outcomes in middle-aged rodents, whereas MSC EVs were less effective. Acute differences in lesion volume following NSC EV treatment were corroborated by MRI in 18-month-old aged rodents. NSC EV treatment has a positive effect on motor function in the aged rodent as indicated by beam walk, instances of foot faults, and strength evaluated by hanging wire test. Increased time with a novel object also indicated that NSC EVs improved episodic memory formation in the rodent. The therapeutic effect of NSC EVs appears to be mediated by altering the systemic immune response. These data strongly support further preclinical development of a NSC EV-based stroke therapy and warrant their testing in combination with FDA-approved stroke therapies.",
keywords = "Neural stem cell extracellular vesicles, Preclinical stroke model, Thromboembolic stroke",
author = "Webb, {Robin L.} and Kaiser, {Erin E.} and Scoville, {Shelley L.} and Thompson, {Tyler A.} and Sumbul Fatima and Pandya, {Chirayukumar D} and Karishma Sriram and Swetenburg, {Raymond L.} and Kumar Vaibhav and Arbab, {Ali Syed} and Babak Baban and Dhandapani, {Krishnan Michael} and Hess, {David C} and Hoda, {MD Nasrul} and Stice, {Steven L.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1007/s12975-017-0599-2",
language = "English (US)",
volume = "9",
pages = "530--539",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",
number = "5",

}

TY - JOUR

T1 - Human Neural Stem Cell Extracellular Vesicles Improve Tissue and Functional Recovery in the Murine Thromboembolic Stroke Model

AU - Webb, Robin L.

AU - Kaiser, Erin E.

AU - Scoville, Shelley L.

AU - Thompson, Tyler A.

AU - Fatima, Sumbul

AU - Pandya, Chirayukumar D

AU - Sriram, Karishma

AU - Swetenburg, Raymond L.

AU - Vaibhav, Kumar

AU - Arbab, Ali Syed

AU - Baban, Babak

AU - Dhandapani, Krishnan Michael

AU - Hess, David C

AU - Hoda, MD Nasrul

AU - Stice, Steven L.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Over 700 drugs have failed in stroke clinical trials, an unprecedented rate thought to be attributed in part to limited and isolated testing often solely in “young” rodent models and focusing on a single secondary injury mechanism. Here, extracellular vesicles (EVs), nanometer-sized cell signaling particles, were tested in a mouse thromboembolic (TE) stroke model. Neural stem cell (NSC) and mesenchymal stem cell (MSC) EVs derived from the same pluripotent stem cell (PSC) line were evaluated for changes in infarct volume as well as sensorimotor function. NSC EVs improved cellular, tissue, and functional outcomes in middle-aged rodents, whereas MSC EVs were less effective. Acute differences in lesion volume following NSC EV treatment were corroborated by MRI in 18-month-old aged rodents. NSC EV treatment has a positive effect on motor function in the aged rodent as indicated by beam walk, instances of foot faults, and strength evaluated by hanging wire test. Increased time with a novel object also indicated that NSC EVs improved episodic memory formation in the rodent. The therapeutic effect of NSC EVs appears to be mediated by altering the systemic immune response. These data strongly support further preclinical development of a NSC EV-based stroke therapy and warrant their testing in combination with FDA-approved stroke therapies.

AB - Over 700 drugs have failed in stroke clinical trials, an unprecedented rate thought to be attributed in part to limited and isolated testing often solely in “young” rodent models and focusing on a single secondary injury mechanism. Here, extracellular vesicles (EVs), nanometer-sized cell signaling particles, were tested in a mouse thromboembolic (TE) stroke model. Neural stem cell (NSC) and mesenchymal stem cell (MSC) EVs derived from the same pluripotent stem cell (PSC) line were evaluated for changes in infarct volume as well as sensorimotor function. NSC EVs improved cellular, tissue, and functional outcomes in middle-aged rodents, whereas MSC EVs were less effective. Acute differences in lesion volume following NSC EV treatment were corroborated by MRI in 18-month-old aged rodents. NSC EV treatment has a positive effect on motor function in the aged rodent as indicated by beam walk, instances of foot faults, and strength evaluated by hanging wire test. Increased time with a novel object also indicated that NSC EVs improved episodic memory formation in the rodent. The therapeutic effect of NSC EVs appears to be mediated by altering the systemic immune response. These data strongly support further preclinical development of a NSC EV-based stroke therapy and warrant their testing in combination with FDA-approved stroke therapies.

KW - Neural stem cell extracellular vesicles

KW - Preclinical stroke model

KW - Thromboembolic stroke

UR - http://www.scopus.com/inward/record.url?scp=85039547348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039547348&partnerID=8YFLogxK

U2 - 10.1007/s12975-017-0599-2

DO - 10.1007/s12975-017-0599-2

M3 - Article

C2 - 29285679

AN - SCOPUS:85039547348

VL - 9

SP - 530

EP - 539

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

IS - 5

ER -